Please login to the form below

Not currently logged in
Email:
Password:

Chugai appoints US CMO

Athos Gianella-Borradori has clinical experience at Novartis and Merck Serono

Japanese company Chugai Pharma has named Dr Athos Gianella-Borradori as chief medical officer of its US subsidiary.

Dr Gianella-Borradori was most recently chief medical officer at Norwegian firm Clavis Pharma having joined the company in 2010 from Merck Serono.

At Merck Serono he served as head of clinical development for small molecules in onco-haematology and his prior experience includes clinical roles across Europe at Novartis, Crucell, Bavarian Nordic and Cyclacel.

The appointment at Chugai Pharma marks Dr Gianella-Borradori's first US role. As chief medical officer he has responsibility for all clinical activity in the US and will participate in a leadership role on scientific and translational committees for its Tokyo-headquartered parent company.

He will also represent Chugai, in which Swiss pharma company Roche owns a majority stake, in its relationships with the US FDA, academia, clinical investigators and patient communities.

30th April 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics